drugset / Trial / NCT00416442

Safety, Tolerability and Pharmacokinetic Study of Single and Multiple Intravenous Doses of RSV604 in Healthy Subjects.

NCT00416442 ↗

Phase 1 Completed 48 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple-dose escalation of RSV604 administered intravenously in healthy subjects.

Timeline

Start
2006-10
Primary completion
2006-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject RSV604 Small molecule — Intravenous

Indications

No indication recorded.